Bioxcel therapeutics to host bxcl701 key opinion leader day to highlight company's investigational, oral innate immune activator for rare form of prostate cancer

New haven, conn., feb. 08, 2023 (globe newswire) -- bioxcel therapeutics, inc. (nasdaq: btai), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will host a key opinion leader (kol) day focused on its lead immuno-oncology program bxcl701 for the investment community on tuesday, february 21, 2023 from 1:00 to 3:00 p.m. et.
BTAI Ratings Summary
BTAI Quant Ranking